Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium.

摘要: Chemotherapeutic agents are active in advanced bladder cancer, and various combinations have shown promising results. The objective of this study was to evaluate the efficacy combination chemotherapy with gemcitabine, paclitaxel, cisplatin patients urothelial carcinoma. Fifty-nine metastatic or locally transitional cell carcinoma urothelium were treated between 2000 2005. No patient had received any previous systemic chemotherapy. All intravenously gemcitabine at a dose 1000 mg/m(2) on days 1 8, paclitaxel 80 50 day 2. Treatment courses repeated every 21 days. After completion four six regimen an intravenous application 28 mg/m(2). Nine (15%) >or=1 visceral site metastases, no Forty-eight (81%) achieved responses treatment (56% complete responses). median actuarial survival 22 months, 1-year 2-year rates 68% 39%, respectively. follow-up 17.5 29 remained alive 25 free disease progression. progression-free for entire group 10 months. time Eastern Cooperative Oncology Group (ECOG) status 0, 1, 2 37.5, 17, 12 Grade 3-4 neutropenia occurred 39% patients. is highly effective tolerable This should be considered as suitable option that deserves further prospective evaluation. ECOG performance important predictive factor survival.